UroStream

Editor’s Note: On August 22–23, 2025, the highly anticipated 2025 Pujiang Uro-Oncology Conference was held in Shanghai, gathering leading experts in urologic oncology from across China and abroad. Among the key topics was the optimization of treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC). Professor Xinan Sheng from Peking University Cancer Hospital delivered an insightful lecture titled “The Combination Revolution in mHSPC — Multi-Strategy Optimization of Patient Management.” His talk provided a systematic review of the current treatment landscape, key challenges, and future directions for mHSPC management.

Recently, the Asian Robotic Urology Section (ARUS), one of the subspecialty committees under the Urological Association of Asia (UAA), held its leadership election and a chair handover ceremony during the UAA Annual Meeting. China’s Academician Xu Zhang has been officially elected as Chair of ARUS, and Professor Gang Zhu has been appointed Secretary-General.

The combination of antibody–drug conjugates (ADCs) with immunotherapy has delivered major breakthroughs across several tumor types, including urothelial carcinoma. At the 2025 European Society for Medical Oncology (ESMO) Congress, results from a pivotal Phase III trial (LBA7) were presented showing that the HER2-targeted ADC disitamab vedotin, combined with the PD-1 inhibitor toripalimab, nearly doubled overall survival compared with chemotherapy as first-line treatment for patients with HER2-expressing locally advanced or metastatic urothelial carcinoma (la/mUC). This novel regimen, centered on an innovative ADC, may redefine first-line therapy—though several key questions remain.

Approximately 5% of urothelial carcinoma (UC) patients present with distant metastasis at diagnosis, and 30% of early-stage patients relapse or develop metastasis despite active treatment. With the emergence of antibody-drug conjugates (ADCs), the median survival of advanced UC patients has extended to 31.5 months. However, the overall survival remains suboptimal. To address this challenge, Professor Dingwei Ye and his team at Fudan University Cancer Hospital initiated a phase II clinical trial of BL-B01D1 for locally advanced or metastatic UC in 2023. The study was presented orally at the 2024 European Society for Medical Oncology (ESMO) Congress, and recently published in the Journal of Clinical Oncology (JCO, IF 41.6).

At the highly anticipated ESMO Congress, a wealth of cutting-edge advances will be presented, with uro-oncology standing out as one of the most vibrant and fast-evolving fields. This year, 22 Late-Breaking Abstracts (LBAs) will be showcased, accounting for nearly half of all oral presentations (45 in total) within the uro-oncology track — a testament to the field’s dynamic research momentum and strong clinical relevance.Oncology Frontier – Urology Frontier has carefully selected ten key studies and invited leading Chinese experts to share their insights and expectations.

Editor’s Note:In recent years, new diagnostic and therapeutic innovations in renal cancer have continued to emerge, providing clinicians with a growing range of treatment options. The widespread adoption of robot-assisted partial nephrectomy (RAPN) has enabled patients to achieve both oncological control and functional preservation. During the 2025 Pujiang Uro-Oncology Academic Conference, leading domestic and international experts in uro-oncology gathered to explore cutting-edge advances and surgical innovations in renal cancer. In this interview, Professor Xu Danfeng from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shares insights from his team’s pioneering surgical concepts and techniques for managing complex hilar renal tumors, offering valuable perspectives for peers in the field.

The 2025 Pujiang Uro-Oncology Academic Conference was successfully held in Shanghai on August 22–23, 2025. Centered on the theme “Precision Breakthroughs · Integrated Innovation · Optimized Continuum of Care,” the conference brought together numerous domestic and international experts to explore innovation in uro-oncology diagnosis and treatment, multidisciplinary collaboration (MDT), and translational research. Oncology Frontier – Urology Frontier interviewed Professor Wei Qiang of West China Hospital, Sichuan University, a member of the conference presidium, to discuss the highlights and driving impact of the event, as well as new advances in robotic surgery for urological tumors.